Shanghai's Hutchison MediPharma Could Close Licensing Deal On Innovative New Crohn's Disease Treatment; Spin-off Likely
This article was originally published in PharmAsia News
Executive Summary
BEIJING - The Shanghai-based Hutchison MediPharma, in the ranks of elite Chinese firms aiming to develop innovative medicines, is likely to sign a licensing agreement on its most promising pipeline drug; the deal would mark a major turning point in the outfit's earnings and its future
You may also be interested in...
China's Tasly Focuses On Plant-based Medicines To Gain Entry To U.S.Market
SHANGHAI - After positive Phase II results in the United States last year, Chinese pharmaceutical company Tasly Group has announced an investment of $40 million to build a manufacturing facility and training center in Maryland to help introduce its Compound Danshen Dripping Pills (CDDP) to the American market
China's Tasly Focuses On Plant-based Medicines To Gain Entry To U.S.Market
SHANGHAI - After positive Phase II results in the United States last year, Chinese pharmaceutical company Tasly Group has announced an investment of $40 million to build a manufacturing facility and training center in Maryland to help introduce its Compound Danshen Dripping Pills (CDDP) to the American market
Japanese Firm Mitsui Invests In China's Hutchison MediPharma; First Step Toward An IPO?
SHANGHAI - Hutchison MediPharma, one of China's leading biotechs, announced Nov. 8 that Tokyo-based venture capital firm Mitsui had acquired a 12.2 percent stake in the company for $12.5 million, generating speculation among China watchers that it could be a first step toward self-funding and an eventual IPO for Hutchison